Rauch, Susanne

New Vaccine Technologies to Combat Outbreak Situations

Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology

SARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune Responses

Cited by 579

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2021) · npj Vaccines

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 165

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2022) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 127

A thermostable messenger RNA based vaccine against rabies

Stitz, L., Vogel, A., Schnee, M., Voss, D., Rauch, S., Mutzke, T., Ketterer, T., Kramps, T., & Petsch, B. (2017) · PLOS Neglected Tropical Diseases

Rabies epidemiology and controlRNA Interference and Gene Delivery

Cited by 117

RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines

Rauch, S., Lutz, J., Kowalczyk, A., Schlake, T., & Heidenreich, R. (2017) · Methods in Molecular Biology

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 57

mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

Rauch, S., Gooch, K., Hall, Y., Salguero, F. J., Dennis, M. J., Gleeson, F. V., Harris, D., Ho, C., Humphries, H. E., Longet, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 48

CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

Hoffmann, D., Corleis, B., Rauch, S., Roth, N., Mühe, J., Halwe, N. J., Ulrich, L., Fricke, C., Schön, J., Kraft, A., et al. (2021) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 48

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models

Corleis, B., Hoffmann, D., Rauch, S., Fricke, C., Roth, N., Gergen, J., Kovacikova, K., Schlottau, K., Halwe, N. J., Ulrich, L., et al. (2023) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 22

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2022) · Vaccines

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 22

Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 18

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates

Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 8